The European Hematology Association 2026 Congress (EHA 2026)

Stockholm, Sweden 11 June 2026 - 14 June 2026

Mezigdomide plus carfilzomib-dexamethasone confers survival benefit in RRMM

06 Aug 2026 by

Treatment with mezigdomide (Mezi) plus carfilzomib and dexamethasone (Kd) significantly improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM) compared with Kd regimen only, according to the phase III SUCCESSOR-2 trial presented at EHA 2026.

Mezigdomide plus carfilzomib-dexamethasone confers survival benefit in RRMM

06 Aug 2026

ASCVD affects 1 in 6 adults with β-thalassaemia; etopivat shows promise

04 Aug 2026 by

Atherosclerotic cardiovascular disease (ASCVD) affects a substantial proportion of adults with β-thalassaemia. It appears to be driven by conventional CV risk factors rather than disease-specific features, according to research presented at EHA2026.

ASCVD affects 1 in 6 adults with β-thalassaemia; etopivat shows promise

04 Aug 2026

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026 by

Treatment with oral venglustat demonstrates superior neurologic outcomes compared with standard enzyme replacement therapy (ERT) in patients with Gaucher disease type 3 (GD3), according to the phase III LEAP2MONO trial presented at EHA 2026.

Venglustat superior to ERT in Gaucher disease type 3

24 Jul 2026

Nipocalimab shows rapid, durable Hgb improvement in adults with wAIHA

14 Jul 2026 by

Treatment with nipocalimab significantly improves haemoglobin (Hgb) levels as early as week 1, with effects persisting through week 24 in patients with warm autoimmune haemolytic anaemia (wAIHA), according to the phase II/III ENERGY trial presented at EHA 2026.

Nipocalimab shows rapid, durable Hgb improvement in adults with wAIHA

14 Jul 2026

Novel SYK inhibitor elicits durable Hb response in autoimmune haemolytic anaemia

11 Jul 2026 by

The highly selective oral spleen tyrosine kinase (SYK) inhibitor sovleplenib has demonstrated significant clinical benefit in patients with warm autoimmune haemolytic anaemia (wAIHA), with durable haemoglobin (Hb) response and a favourable safety profile, as shown in the phase III ESLIM-02 trial.

Novel SYK inhibitor elicits durable Hb response in autoimmune haemolytic anaemia

11 Jul 2026

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

10 Jul 2026 by

The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

10 Jul 2026

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026 by

In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026

Efgartigimod improves platelet response in primary ITP

07 Jul 2026 by

The use of efgartigimod in adult patients with primary immune thrombocytopenia (ITP) results in higher platelet response with no increase in serious adverse events (AEs), reports a meta-analysis of phase III randomized controlled trials (RCTs).

Efgartigimod improves platelet response in primary ITP

07 Jul 2026

Pooled analysis validates iptacopan safety for PNH

06 Jul 2026 by

A pooled analysis presented at EHA 2026 demonstrates the long-term safety of the oral proximal complement inhibitor iptacopan in the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Pooled analysis validates iptacopan safety for PNH

06 Jul 2026

Upfront immunosuppression regimen improves survival in acquired haemophilia A

05 Jul 2026 by

In the first-line treatment of acquired haemophilia A (AHA), the use of an intravenous (IV) pulse-dose immunosuppression regimen that combines cyclophosphamide, dexamethasone, and rituximab appears to result in faster remission and improved survival compared with traditional oral sequential prednisone-based regimens, according to a study.

Upfront immunosuppression regimen improves survival in acquired haemophilia A

05 Jul 2026